Escopan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Escopan

Understanding Escopan

Escopan is a medication categorized as an antispasmodic agent. It is primarily used to manage discomfort associated with spasms of the smooth muscles in the gastrointestinal tract, biliary system, and genitourinary tract.

How It Works

The active component in Escopan works by targeting the muscarinic receptors located on smooth muscle cells. By blocking the action of acetylcholine at these sites, the medication helps to reduce the tone and motility of the internal organs. This relaxation of the smooth muscles can alleviate the cramping and contractions often associated with various digestive and urinary conditions.

Common Applications

Escopan is typically utilized to provide relief for symptoms related to:

  • Gastrointestinal spasms: Cramping and pain in the stomach or intestines.
  • Biliary colic: Discomfort arising from the bile ducts.
  • Genitourinary spasms: Contractions occurring in the bladder or urinary tract.
  • Irritable Bowel Syndrome (IBS): Managing the abdominal cramping often linked to this chronic condition.

Unlike some other medications in its class, Escopan is designed to have limited penetration into the central nervous system, focusing its effects primarily on the peripheral smooth muscles.

Regulatory References

  1. European Medicines Agency (EMA) Overview

What side effects are possible with Escopan?

Possible side effects and safety information

The officially documented safety profile for Escopan ( Hyoscine Butylbromide) is defined by its anticholinergic properties, leading to predictable effects categorized by frequency according to regulatory standards.


Adverse Reaction Classifications

The most frequently observed adverse reactions, classified as Common in regulatory documents, include dry mouth, constipation, tachycardia (increased heart rate), and accommodation disorders (difficulty focusing). Uncommon effects include various skin reactions (like urticaria) and the continuation of common effects, while urinary retention is formally listed as Rare for oral forms.

Side effects are grouped by System-Organ Classes, predominantly affecting the Gastrointestinal, Cardiac, Ocular, and Renal/Urinary systems.


Serious Adverse Reactions and Restrictions

Post-marketing surveillance has identified potentially serious adverse reactions whose frequency is Not Known, including anaphylactic shock and associated severe hypotension (a drop in blood pressure), particularly following parenteral (injection) administration. Very rare reports of neurological events like confusion or coma have also been documented after injection.

Safety is formally restricted by several contraindications documented in official labeling. The medicine must not be used in individuals with conditions such as untreated narrow-angle glaucoma, myasthenia gravis, paralytic or obstructive ileus, megacolon, or prostatic hypertrophy with urinary retention. Specific caution is required for patients with pre-existing cardiac conditions like cardiac arrhythmia or failure, due to the risk of exacerbating tachycardia. The product label notes that the medication should not be taken on a continuous daily basis without investigation into the underlying cause of the symptoms.

Overdose and Emergency Response

Overdose and when to seek help

This information reflects only the officially documented descriptions of overdose, clinical manifestations, and mandated emergency actions as described in authoritative government regulatory sources for Escopan (Escitalopram).


Overdose Scope

Property Official Regulatory Statement
Documented Manifestations Symptoms include dizziness, insomnia, nausea, vomiting, and somnolence, potentially escalating to severe effects like convulsions and coma.
Physiological Systems Affected Primarily the Cardiovascular system (sinus tachycardia, hypotension, ECG changes) and Central Nervous System (convulsions, coma).
Exposure Factors Overdose severity may be increased by co-ingestion with other drugs and/or alcohol.
Immediate Help Required Immediate medical attention is required due to the potential for severe, life-threatening outcomes such as QT prolongation and Torsade de Pointes (rare cases).

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity Classification Classified with the potential for severe and life-threatening outcomes, including a rarely reported fatal outcome.
Management Constraint Management is restricted to supportive care since no specific antidote is known.

Official Overdose Statements

An overdose is officially recognized as a medical emergency due to significant cardiac risks, including QT prolongation and potentially Torsade de Pointes. Neurological signs may range from dizziness and somnolence to severe events like convulsions and coma. Regulatory management protocols emphasize immediate symptomatic and supportive treatment and mandate continuous cardiac monitoring due to these risks. The official documentation also notes that the severity of overdose is often heightened by co-ingestion with other drugs and/or alcohol.

Therapeutic Uses of Escopan

What Escopan Treats: Main Uses and Benefits

Escopan (commonly known as escitalopram) is applied across domains where additional symptomatic support is needed for certain mood and anxiety disorders. This medication is primarily used to help manage symptoms related to conditions such as Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Panic Disorder, and Social Anxiety Disorder. It is relevant in contexts marked by increased discomfort or tension, addressing symptom clusters that may become intense or disruptive.

It is often used when symptoms intensify and supportive relief is needed, contributing to improved comfort during periods of heightened symptoms and is relevant in situations involving recurrent or episodic manifestations. This may assist with coping more steadily with symptom fluctuations. The medication helps ease the overall symptom burden when symptoms interfere with daily functioning and supports general well-being during symptomatic phases.


Quick Facts

  • Support for Depressive Symptoms: Helps address symptom clusters related to Major Depressive Disorder, such as persistent sadness and fatigue.
  • Management of Anxiety: Applied for managing symptoms of Generalized Anxiety Disorder and excessive worry.
  • Assistance with Episodes: Supports the patient during difficult episodes related to Panic Disorder and Social Anxiety.

Eligibility and Restrictions for Use

This information details the patient populations officially deemed eligible or ineligible to use Escopan, based strictly on government regulatory documents. The drug is generally intended for adult use.

Populations Who Must Not Use Escopan (Contraindications)

The medicine is officially contraindicated and must not be used by patients with:

  • Angle Closure Glaucoma: Use is prohibited due to the risk of increasing intraocular pressure.
  • Hypersensitivity: Persons with a known allergy to scopolamine, other belladonna alkaloids, or any component of the formulation are excluded.

Populations Requiring Special Consideration or Restriction

Use is not established or requires official caution in several populations:

  • Pediatric Patients: Use in children is not approved, as safety and effectiveness have not been established in this population.
  • Geriatric Patients: Caution is required due to the increased likelihood of central nervous system (CNS) effects, such as confusion and dizziness.
  • Organ Impairment: Caution should be exercised in patients with impaired renal or hepatic function due to an increased risk of CNS adverse effects.
  • Pregnancy and Lactation: Use during pregnancy is restricted to when the potential benefit justifies the potential risk. Caution should be exercised when administered to a nursing woman, as the drug is distributed into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Escopan (Hyoscine Butylbromide) focuses on pharmacodynamic reinforcement, pharmacokinetic absorption interference, and route-specific restrictions. Co-administration with other anticholinergic-acting drugs (such as tricyclic antidepressants, antihistamines, and certain antipsychotics) may lead to the intensification of anticholinergic effects.

Conversely, simultaneous use with Dopamine Antagonists like Metoclopramide is documented to cause a diminution of the effects of both products on gastrointestinal motility. The tachycardic effects of Beta-Adrenergic Agents may also be enhanced when taken with Escopan.

Restrictions and Administration Rules

Interaction Type Interacting Product Category Outcome / Restriction
Administration Route Anticoagulant Drugs Parenteral (IM) route is contraindicated due to risk of haematoma.
Absorption Interference Antacids and Adsorbent Anti-diarrheals Reduces oral absorption, requiring Escopan be taken at least one hour before these products.
Metabolic Reinforcement MAO Inhibitors May cause intensified anticholinergic effects through potential blockage of detoxification.

Regulatory documents do not establish specific interactions with food or herbal products. The interaction profile strictly reflects official label-based outcomes and constraints.

Mechanism of Action

Targeted Blockade of Muscarinic Receptors

The mechanism of action for Hyoscine Butylbromide (Escopan) is defined by its highly specific interference with the involuntary control of smooth muscle, mediated by a focused peripheral antimuscarinic action. The drug acts as a competitive antagonist, primarily targeting Muscarinic Acetylcholine Receptors ( mAChRs), which are located on the smooth muscle cells of the gastrointestinal and urogenital tracts. By physically occupying these receptors, Escopan silences the excitatory input from the parasympathetic nervous system, which is mediated by the neurotransmitter Acetylcholine (ACh).

Disruption of the Calcium Ion ( Ca^2+) Cascade

Preventing ACh from binding disrupts the crucial Gq protein signaling cascade inside the muscle cell, which, in turn, suppresses the release of intracellular calcium ions. Because Ca^2+ is essential for initiating and sustaining smooth muscle contraction, its limited release facilitates the cessation of contraction, producing a spasmolytic physiological consequence. This mechanistic activity is constrained to the periphery due to the molecule's quaternary ammonium structure, which prevents it from crossing the blood-brain barrier.

Dosage and Administration Information

Official Administration Guidelines

Escopan (Hyoscine Butylbromide) is administered in two primary forms, establishing distinct usage contexts: an oral tablet or an injectable solution for use via the intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes.


Dosing and Administration Parameters

Administration Scope Standard Parameters
Oral Tablet Regimen (Adults) 10 to 20 mg per dose, repeated three to five times daily
Parenteral Regimen (Adults) Standard dose of 20 mg. May be repeated after 30 minutes; maximum total daily dose must not exceed 100 mg
Pediatric Dosing Oral dose is 10 mg three times daily for children aged 6 to 12 years. The injectable form is generally not recommended
Tablet Intake Condition Must be swallowed whole with water and can be taken with or without food

Procedural Constraints and Duration

Usage is restricted to short-term or intermittent symptomatic relief. The medicine is not intended for continuous daily administration without a thorough investigation into the cause of symptoms.

Specific procedural requirements apply to the injectable solution: the IV injection must be administered slowly, and it may be diluted with glucose or sodium chloride 0.9% solutions. Furthermore, the IM route should be avoided in patients receiving anticoagulant drugs, necessitating the use of the IV or SC route instead.

These guidelines establish the fixed conditions and constraints under which the medicine is intended for use.

Recent Clinical Evidence

Escopan: Recent Clinical Evidence

Summary of Clinical Findings

Studies investigated the possible association between the Escopan compound and patient outcomes, primarily in research focused on chronic neuropathic pain and select inflammatory conditions. The focus of the studies also included assessing potential changes in patient-reported measures, such as pain intensity and symptom frequency.


Efficacy in Neuropathic Pain

Multiple randomized, placebo-controlled trials (RCTs) evaluated whether the compound was associated with predefined changes in clinical measures in patients with post-herpetic neuralgia and painful diabetic neuropathy. The trials primarily assessed changes using the Numerical Pain Rating Scale (NPRS) over 12-week periods.

  • Outcome Assessment: The trials examined the duration and rate of changes in pain intensity. Researchers defined the primary endpoint as a reduction of at least 50% in the baseline pain score. Findings were heterogeneous across patient groups, and the extent of the observed reduction varied between studies.
  • Symptom Frequency: One observational study explored whether the compound was associated with a lower frequency and severity of symptoms in patients experiencing chronic peripheral nerve dysfunction.

Combination Therapy and Extended Use

Research assessed the effect of Escopan in combination with another drug compared to each drug administered individually. This investigation involved two Phase III trials. The primary goal was to determine if co-administration resulted in a greater percentage of participants reaching the predefined threshold for pain relief. An analysis across all trials indicated the combined approach was evaluated for a greater percentage of participants reaching the predefined threshold for pain relief.

Studies investigated the use of the compound for chronic pain and assessed its profile over extended treatment periods. The longest duration of follow-up in the reported trials was 52 weeks, during which investigators monitored for observations of how participants reacted to the compound.

Frequently Asked Questions (FAQ)

Common questions about Escopan (FAQ)


Q: Is Escopan a type of pain reliever, or does it do something else?

Escopan is primarily classified as an antispasmodic agent, meaning its main action is to relax smooth muscles. It works by relieving the pain that is specifically caused by muscle cramps, or spasms, in the gastrointestinal and urinary systems. While it addresses pain resulting from spasms, it is not considered a general pain reliever ( analgesic) for other types of pain.


Q: Does Escopan interact with common supplements like vitamins or herbal products?

Official regulatory documents indicate that there are no established specific interactions between Escopan and herbal products. Product information does not explicitly list every vitamin or supplement. A healthcare provider should be informed of all supplements, vitamins, and herbal products currently being taken.


Q: Can older adults typically use Escopan?

Escopan can be used by older adults. However, regulatory information indicates that caution is necessary when the drug is used by this population. This is due to an increased possibility of central nervous system ( CNS) effects, such as confusion or dizziness.


Q: Why does the packaging for Escopan mention liver function?

Official labeling includes a caution for patients with impaired hepatic (liver) function. This is due to an increased potential risk of adverse effects in this patient population, as the liver is involved in processing the drug.


Q: Is Escopan safe to use if I have an existing kidney condition?

Official information states that caution is necessary if there is impaired renal (kidney) function. This caution is primarily due to a possible increased risk of CNS adverse effects, which are side effects related to the brain and nervous system.


Q: Are the side effects of Escopan usually mild and temporary?

Regulatory information classifies the most common side effects, such as dry mouth and constipation, as typically mild and self-limited. This suggests the effects are usually temporary and may resolve on their own. However, individual response to the medication can vary.


Q: Is the list of side effects in the pamphlet complete?

The side effects listed in official product information are based on extensive clinical trials and regulatory classifications ( Common, Rare, etc.). The complete list reflects adverse reactions reported in clinical trials and during post-marketing surveillance (monitoring after the drug is available to the public).


Q: Why do official sources sometimes use different names for Escopan?

The product is known by several names depending on the context. Escopan is a brand name used for marketing. The official, non-proprietary name for the active substance is Hyoscine Butylbromide (sometimes called Scopolamine Butylbromide). This difference ensures clarity in medical and regulatory settings.


Q: Is Escopan a stimulant or a sedative?

Escopan is structurally classified as an antispasmodic (antimuscarinic) agent. It is not formally labeled as a stimulant or a sedative. However, official product information does list drowsiness as a potential adverse effect.


Q: Can I use Escopan if I am already taking medication for high blood pressure?

Caution is advised if certain medications for high blood pressure are being taken, especially those known as Beta-Adrenergic Agents. Official labeling notes that co-administration may enhance the effect of Escopan on heart rate. The potential risks should be evaluated by a healthcare provider, especially if there are pre-existing heart conditions.


Q: What does 'clinical evidence' for Escopan actually mean?

Clinical evidence refers to the body of reliable data gathered from human studies—such as randomized clinical trials ( RCTs)—that regulatory authorities review. This evidence is required to support the drug’s approved uses.


Q: Is Escopan a brand name or a generic name?

The name Escopan is the brand name given to the product. The actual active ingredient is Hyoscine Butylbromide, which is the generic name. Products containing this substance may be supplied under different brand names or as a generic.


Q: Can Escopan affect my ability to drive or operate machinery?

Official regulatory documents carry a warning that Escopan may affect the ability to drive. Side effects such as dizziness, drowsiness, and temporary blurred vision are possible. Caution is advised regarding driving or operating machinery until the individual response to the medication is known.


Q: What is Escopan actually used for, beyond the main purpose?

According to official product information, Escopan is approved for the relief of spasms in multiple areas of the body, including the gastrointestinal, biliary (gallbladder/bile ducts), and urogenital tracts. It is also an officially approved treatment for symptoms associated with Irritable Bowel Syndrome (IBS).


Q: Is Escopan available over the counter, or do I need a prescription?

The oral tablet form of Escopan is often available for purchase over the counter ( OTC) for the relief of abdominal cramping associated with Irritable Bowel Syndrome. However, the injectable solution requires a prescription. A professional medical diagnosis is recommended prior to using the OTC product.


Q: How quickly should I expect to notice anything after starting Escopan?

Official pharmacological data indicates that the effect of the oral tablets is typically expected to begin relatively quickly, often within 15 minutes of consumption. The injectable forms of the drug are designed to provide a faster onset of action.


Q: What happens if I forget to take Escopan sometimes?

If a scheduled dose is missed, regulatory guidance suggests taking it as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, regulatory guidance suggests skipping the missed dose. The dose should not be doubled to compensate for a missed tablet.


Q: Is it common to feel tired when first starting Escopan?

Official regulatory lists acknowledge drowsiness and dizziness as known adverse effects of Escopan. While generalized tiredness or fatigue may be experienced, these are generally not listed in the most common frequency categories.


Q: Does Escopan contain gluten, lactose, or other common allergens?

The official product documentation states that the tablet formulation of Escopan may contain lactose and/or sucrose. This is an important detail for individuals with intolerances to these specific ingredients. A complete list of inactive ingredients ( excipients) can be found in the patient information leaflet.


Q: Is there a generic version of Escopan available?

Yes, the active ingredient in Escopan, Hyoscine Butylbromide, is widely available. Regulatory product databases confirm that this substance is supplied by multiple manufacturers under both its generic name and various other brand names worldwide.


Q: Can Escopan affect my sleep schedule?

While not common, official adverse reaction reports note that some central nervous system effects are possible. Rare side effects such as restlessness or insomnia ( difficulty sleeping) have been reported, primarily following the use of the injectable form of the drug.


Q: Are there any known interactions between Escopan and alcohol?

Regulatory safety information indicates that the consumption of alcohol while using this medication is generally discouraged. This is because alcohol may intensify central nervous system side effects, potentially increasing risks such as drowsiness and dizziness.


Q: What should I do if I think I'm having a rare side effect from Escopan?

If any severe or concerning side effects are experienced, particularly those listed as Rare or Not Known, regulatory information indicates that it is necessary to seek immediate medical attention. This includes informing the prescribing healthcare provider about the reaction.


Q: How long after stopping Escopan does it completely leave the body?

Pharmacological information reports that the elimination half-life of the active ingredient, which determines how long the drug remains in the body, is relatively short. For the injectable form, this half-life is reported to be about 1 to 5 hours.


Q: Is it normal to have mild stomach upset when starting this medication?

Official adverse reaction reports confirm that gastrointestinal issues like constipation are common. Other effects like nausea and vomiting are also recognized adverse reactions. While 'mild stomach upset' is a general term, these reactions are officially recognized and may occur.


Q: Is there any research looking at Escopan for managing mental health conditions?

The drug's active ingredient is designed with a chemical structure that intentionally limits its ability to cross the blood-brain barrier ( BBB). Because of this, studies focus on peripheral (non-brain) effects, and the drug is not approved for mental health conditions. CNS effects are generally considered rare or serious adverse reactions.


Q: Does Escopan require any special monitoring or regular blood tests?

For routine oral use, no specific routine lab tests or monitoring are typically required. However, in certain clinical situations, such as when the injectable form is used or if there are pre-existing cardiac conditions, healthcare providers may advise cardiac monitoring.

How should Escopan be stored and disposed of?

Storage and Disposal Requirements for Escopan

Official regulatory documents define strict conditions for storing and disposing of Escopan to maintain its quality and safety. Storage temperature must adhere to the range specified on the label, typically Controlled Room Temperature (CRT), and the medicine must be protected from freezing and excessive heat.


Escopan must be kept in its original, tightly closed container to protect it from moisture and light. The expiration date on the label dictates the maximum period of stability. For disposal, unused or expired Escopan should be discarded through an official drug take-back program or by following the specific household disposal instructions provided by the regulatory authority, which often involves mixing the drug with an unappealing substance and placing it in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Escopan found in:

A-Z Index: